Trends on the Role of PET in Drug Development.:
Drug development is very expensive and a fight against time. PET offers possibilities to speed up this process by adding unique in vivo information on pharmacokinetics/dynamics of a drug at an early stage. This information can help decision makers to move the drug in the drug development process or...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Singapore :
World Scientific,
2012.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Drug development is very expensive and a fight against time. PET offers possibilities to speed up this process by adding unique in vivo information on pharmacokinetics/dynamics of a drug at an early stage. This information can help decision makers to move the drug in the drug development process or to decide to stop further developments. This unique and complete book highlights the different ways PET can be used and describes the latest trends in the various disciplines within nuclear medicine to further improve methodologies and increase the number of tools to accelerate drug development. Var. |
| Beschreibung: | 2.2 Influence of ionic liquid and tertiary alcohols on [18F]fluorination. |
| Beschreibung: | 1 online resource (799 pages) |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9789814317740 9814317748 |
Internformat
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn794328395 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 120528s2012 si ob 001 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d YDXCP |d OHS |d N$T |d OCLCQ |d OCLCF |d OCLCQ |d OCLCO |d OCLCQ |d E7B |d STF |d UKDOC |d OCLCQ |d AGLDB |d OCLCQ |d OCLCO |d OCLCA |d VNS |d VTS |d REC |d AU@ |d OTZ |d OCLCQ |d M8D |d OCLCO |d UKAHL |d OCLCQ |d OCLCA |d OCLCQ |d OCLCA |d OCLCO |d OCL |d OCLCQ |d OCLCO |d OCLCQ |d SXB |d OCLCQ | ||
| 019 | |a 797852226 |a 1058497296 |a 1086507647 | ||
| 020 | |a 9789814317740 |q (electronic bk.) | ||
| 020 | |a 9814317748 |q (electronic bk.) | ||
| 020 | |z 981431773X | ||
| 020 | |z 9789814317733 | ||
| 035 | |a (OCoLC)794328395 |z (OCoLC)797852226 |z (OCoLC)1058497296 |z (OCoLC)1086507647 | ||
| 050 | 4 | |a RM301.25 | |
| 060 | 4 | |a QV 745 | |
| 072 | 7 | |a MED |x 023000 |2 bisacsh | |
| 072 | 7 | |a MED |x 058170 |2 bisacsh | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 072 | 7 | |a MED |x 072000 |2 bisacsh | |
| 082 | 7 | |a 615.19 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Elsinga, Philip H. | |
| 245 | 1 | 0 | |a Trends on the Role of PET in Drug Development. |
| 260 | |a Singapore : |b World Scientific, |c 2012. | ||
| 300 | |a 1 online resource (799 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 505 | 0 | |a The Editors; Contributors; Preface; 1 Introduction on PET. Description of Basics and Principles Aren van Waarde; References; 2 Drug Development in the Pharmaceutical Industry Adrian D. Nunn; 1. Introduction; 2. Drug Approval Rates; 3. Costs of Each Stage; 4. Efficiency of Drug Development; 5. Changing Healthcare Model; 6. Comparative Effectiveness; 7. Personalized Medicine; 8. Regulatory Issues; 9. Conclusions; References; 3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines R. Paul Maguire; 1. Summary. | |
| 505 | 8 | |a 2. FDA Critical Path Initiative -- Drug Development Challenge3. Drug Development Process Decision Points; 3.1 Phases of drug development; 4. Imaging Biomarkers in General; 4.1 Imaging biomarkers for early decision making; 4.2 Diagnostics; 4.2.1 Smaller likelihood ratio; 4.3 Markers of disease; 5. Imaging Biomarkers Other than Molecular Imaging; 6. Biomarkers Other than Imaging; 7. Receptor Occupancy; 7.1 Determination of in vivo KD; 7.2 Typical RO study designs; 7.3 Assumptions; 8. Thresholds for Decision Making; 8.1 Efficacy and occupancy at G-coupled protein receptors. | |
| 505 | 8 | |a 9. Sources of Imprecision9.1 Instrument sensitivity; 9.2 Variability of PK; 10. Safety of Molecular Imaging Probes; 11. Ideal Molecular Imaging Ligand; 11.1 Safety; 11.2 Affinity; 11.3 Non-specific binding; 11.4 Selectivity; 11.5 Easy deployment and implementation; 12. Models of PET-Pharmacokinetics -- Data Analysis; 13. Industry Academic Collaboration; 13.1 Labeling available chemical matter; 13.2 Translational imaging; 13.3 Customized therapies -- companion diagnostics; 14. Summary; References; 4 What is the Role of Positron Emission Tomography in Drug Development? Timothy J. McCarthy. | |
| 505 | 8 | |a 1. Introduction2. Biomarker Definitions; 3. PET as a Tool for Proof of Target; 4. PET as a Tool for Proof of Mechanism; 5. PET as a Tool for Proof of Efficacy; 6. Summary and Conclusions; References; 5 Review of 11C Preparations and Examples in Drug Development Farhad Karimi and Bengt Långstrom; 1. Choice of Radionuclide; 2. 11C Compounds; 2.1 11C precursor; 2.2 11C chemistry based on [11C]methyl iodide/triflate; 2.2.1 Palladium-mediated C-C bond formation; 2.3 11C Chemistry based on [11C]carbon monoxide; 2.3.1 [11C]Carbon monoxide insertion. | |
| 505 | 8 | |a 2.3.2 Organo metals mediated 11C-carbonylation reaction2.3.2.1 Palladium-mediated 11C-carbonylation reaction; 2.3.2.2 Selenium-mediated 11C-carbonylation reaction; 2.3.2.3 Rhodium-mediated 11C-carbonylation reaction; 2.3.2.4 Radical-mediated carbonylation reactions; 3. Endogenous PET-Radiopharmaceuticals; 4. Automated Synthetic Devices; References; 6 The Role of Recent Development of 18F Radiochemistry in Drug Development Farhad Karimi and Bengt Långstrom; 1. Introduction; 2. Nucleophilic 18F Fluorination; 2.1 Basic chemistry. | |
| 500 | |a 2.2 Influence of ionic liquid and tertiary alcohols on [18F]fluorination. | ||
| 520 | |a Drug development is very expensive and a fight against time. PET offers possibilities to speed up this process by adding unique in vivo information on pharmacokinetics/dynamics of a drug at an early stage. This information can help decision makers to move the drug in the drug development process or to decide to stop further developments. This unique and complete book highlights the different ways PET can be used and describes the latest trends in the various disciplines within nuclear medicine to further improve methodologies and increase the number of tools to accelerate drug development. Var. | ||
| 588 | 0 | |a Print version record. | |
| 504 | |a Includes bibliographical references and index. | ||
| 650 | 0 | |a Drug development. |0 http://id.loc.gov/authorities/subjects/sh97007921 | |
| 650 | 0 | |a Tomography, Emission. |0 http://id.loc.gov/authorities/subjects/sh85135956 | |
| 650 | 0 | |a Pharmaceutical technology. |0 http://id.loc.gov/authorities/subjects/sh85100590 | |
| 650 | 0 | |a Drugs |x Design. |0 http://id.loc.gov/authorities/subjects/sh88001157 | |
| 650 | 2 | |a Drug Design | |
| 650 | 2 | |a Technology, Pharmaceutical | |
| 650 | 2 | |a Positron-Emission Tomography | |
| 650 | 2 | |a Tomography, Emission-Computed |0 https://id.nlm.nih.gov/mesh/D014055 | |
| 650 | 6 | |a Médicaments |x Développement. | |
| 650 | 6 | |a Tomographie par émission. | |
| 650 | 6 | |a Techniques pharmaceutiques. | |
| 650 | 6 | |a Médicaments |x Conception. | |
| 650 | 7 | |a MEDICAL |x Drug Guides. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Nursing |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacy. |2 bisacsh | |
| 650 | 7 | |a Drugs |x Design |2 fast | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Pharmaceutical technology |2 fast | |
| 650 | 7 | |a Tomography, Emission |2 fast | |
| 700 | 1 | |a Van Waarde, Aren. | |
| 700 | 1 | |a Paans, Anne M. J. | |
| 776 | 0 | 8 | |i Print version: |a Elsinga, Philip H. |t Trends on the Role of PET in Drug Development. |d Singapore : World Scientific, ©2012 |z 9789814317733 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457199 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH25565236 | ||
| 938 | |a 123Library |b 123L |n 114803 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL919100 | ||
| 938 | |a ebrary |b EBRY |n ebr10563508 | ||
| 938 | |a EBSCOhost |b EBSC |n 457199 | ||
| 938 | |a YBP Library Services |b YANK |n 7223101 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn794328395 |
|---|---|
| _version_ | 1816881795698786304 |
| adam_text | |
| any_adam_object | |
| author | Elsinga, Philip H. |
| author2 | Van Waarde, Aren Paans, Anne M. J. |
| author2_role | |
| author2_variant | w a v wa wav a m j p amj amjp |
| author_facet | Elsinga, Philip H. Van Waarde, Aren Paans, Anne M. J. |
| author_role | |
| author_sort | Elsinga, Philip H. |
| author_variant | p h e ph phe |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM301 |
| callnumber-raw | RM301.25 |
| callnumber-search | RM301.25 |
| callnumber-sort | RM 3301.25 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | The Editors; Contributors; Preface; 1 Introduction on PET. Description of Basics and Principles Aren van Waarde; References; 2 Drug Development in the Pharmaceutical Industry Adrian D. Nunn; 1. Introduction; 2. Drug Approval Rates; 3. Costs of Each Stage; 4. Efficiency of Drug Development; 5. Changing Healthcare Model; 6. Comparative Effectiveness; 7. Personalized Medicine; 8. Regulatory Issues; 9. Conclusions; References; 3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines R. Paul Maguire; 1. Summary. 2. FDA Critical Path Initiative -- Drug Development Challenge3. Drug Development Process Decision Points; 3.1 Phases of drug development; 4. Imaging Biomarkers in General; 4.1 Imaging biomarkers for early decision making; 4.2 Diagnostics; 4.2.1 Smaller likelihood ratio; 4.3 Markers of disease; 5. Imaging Biomarkers Other than Molecular Imaging; 6. Biomarkers Other than Imaging; 7. Receptor Occupancy; 7.1 Determination of in vivo KD; 7.2 Typical RO study designs; 7.3 Assumptions; 8. Thresholds for Decision Making; 8.1 Efficacy and occupancy at G-coupled protein receptors. 9. Sources of Imprecision9.1 Instrument sensitivity; 9.2 Variability of PK; 10. Safety of Molecular Imaging Probes; 11. Ideal Molecular Imaging Ligand; 11.1 Safety; 11.2 Affinity; 11.3 Non-specific binding; 11.4 Selectivity; 11.5 Easy deployment and implementation; 12. Models of PET-Pharmacokinetics -- Data Analysis; 13. Industry Academic Collaboration; 13.1 Labeling available chemical matter; 13.2 Translational imaging; 13.3 Customized therapies -- companion diagnostics; 14. Summary; References; 4 What is the Role of Positron Emission Tomography in Drug Development? Timothy J. McCarthy. 1. Introduction2. Biomarker Definitions; 3. PET as a Tool for Proof of Target; 4. PET as a Tool for Proof of Mechanism; 5. PET as a Tool for Proof of Efficacy; 6. Summary and Conclusions; References; 5 Review of 11C Preparations and Examples in Drug Development Farhad Karimi and Bengt Långstrom; 1. Choice of Radionuclide; 2. 11C Compounds; 2.1 11C precursor; 2.2 11C chemistry based on [11C]methyl iodide/triflate; 2.2.1 Palladium-mediated C-C bond formation; 2.3 11C Chemistry based on [11C]carbon monoxide; 2.3.1 [11C]Carbon monoxide insertion. 2.3.2 Organo metals mediated 11C-carbonylation reaction2.3.2.1 Palladium-mediated 11C-carbonylation reaction; 2.3.2.2 Selenium-mediated 11C-carbonylation reaction; 2.3.2.3 Rhodium-mediated 11C-carbonylation reaction; 2.3.2.4 Radical-mediated carbonylation reactions; 3. Endogenous PET-Radiopharmaceuticals; 4. Automated Synthetic Devices; References; 6 The Role of Recent Development of 18F Radiochemistry in Drug Development Farhad Karimi and Bengt Långstrom; 1. Introduction; 2. Nucleophilic 18F Fluorination; 2.1 Basic chemistry. |
| ctrlnum | (OCoLC)794328395 |
| dewey-full | 615.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.19 |
| dewey-search | 615.19 |
| dewey-sort | 3615.19 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06745cam a2200841 a 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn794328395</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |n|---|||||</controlfield><controlfield tag="008">120528s2012 si ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">YDXCP</subfield><subfield code="d">OHS</subfield><subfield code="d">N$T</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">E7B</subfield><subfield code="d">STF</subfield><subfield code="d">UKDOC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">AGLDB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">VNS</subfield><subfield code="d">VTS</subfield><subfield code="d">REC</subfield><subfield code="d">AU@</subfield><subfield code="d">OTZ</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCO</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">SXB</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">797852226</subfield><subfield code="a">1058497296</subfield><subfield code="a">1086507647</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789814317740</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9814317748</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">981431773X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9789814317733</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)794328395</subfield><subfield code="z">(OCoLC)797852226</subfield><subfield code="z">(OCoLC)1058497296</subfield><subfield code="z">(OCoLC)1086507647</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM301.25</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 745</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">023000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">058170</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">072000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.19</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Elsinga, Philip H.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Trends on the Role of PET in Drug Development.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Singapore :</subfield><subfield code="b">World Scientific,</subfield><subfield code="c">2012.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (799 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">The Editors; Contributors; Preface; 1 Introduction on PET. Description of Basics and Principles Aren van Waarde; References; 2 Drug Development in the Pharmaceutical Industry Adrian D. Nunn; 1. Introduction; 2. Drug Approval Rates; 3. Costs of Each Stage; 4. Efficiency of Drug Development; 5. Changing Healthcare Model; 6. Comparative Effectiveness; 7. Personalized Medicine; 8. Regulatory Issues; 9. Conclusions; References; 3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines R. Paul Maguire; 1. Summary.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2. FDA Critical Path Initiative -- Drug Development Challenge3. Drug Development Process Decision Points; 3.1 Phases of drug development; 4. Imaging Biomarkers in General; 4.1 Imaging biomarkers for early decision making; 4.2 Diagnostics; 4.2.1 Smaller likelihood ratio; 4.3 Markers of disease; 5. Imaging Biomarkers Other than Molecular Imaging; 6. Biomarkers Other than Imaging; 7. Receptor Occupancy; 7.1 Determination of in vivo KD; 7.2 Typical RO study designs; 7.3 Assumptions; 8. Thresholds for Decision Making; 8.1 Efficacy and occupancy at G-coupled protein receptors.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">9. Sources of Imprecision9.1 Instrument sensitivity; 9.2 Variability of PK; 10. Safety of Molecular Imaging Probes; 11. Ideal Molecular Imaging Ligand; 11.1 Safety; 11.2 Affinity; 11.3 Non-specific binding; 11.4 Selectivity; 11.5 Easy deployment and implementation; 12. Models of PET-Pharmacokinetics -- Data Analysis; 13. Industry Academic Collaboration; 13.1 Labeling available chemical matter; 13.2 Translational imaging; 13.3 Customized therapies -- companion diagnostics; 14. Summary; References; 4 What is the Role of Positron Emission Tomography in Drug Development? Timothy J. McCarthy.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">1. Introduction2. Biomarker Definitions; 3. PET as a Tool for Proof of Target; 4. PET as a Tool for Proof of Mechanism; 5. PET as a Tool for Proof of Efficacy; 6. Summary and Conclusions; References; 5 Review of 11C Preparations and Examples in Drug Development Farhad Karimi and Bengt Långstrom; 1. Choice of Radionuclide; 2. 11C Compounds; 2.1 11C precursor; 2.2 11C chemistry based on [11C]methyl iodide/triflate; 2.2.1 Palladium-mediated C-C bond formation; 2.3 11C Chemistry based on [11C]carbon monoxide; 2.3.1 [11C]Carbon monoxide insertion.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">2.3.2 Organo metals mediated 11C-carbonylation reaction2.3.2.1 Palladium-mediated 11C-carbonylation reaction; 2.3.2.2 Selenium-mediated 11C-carbonylation reaction; 2.3.2.3 Rhodium-mediated 11C-carbonylation reaction; 2.3.2.4 Radical-mediated carbonylation reactions; 3. Endogenous PET-Radiopharmaceuticals; 4. Automated Synthetic Devices; References; 6 The Role of Recent Development of 18F Radiochemistry in Drug Development Farhad Karimi and Bengt Långstrom; 1. Introduction; 2. Nucleophilic 18F Fluorination; 2.1 Basic chemistry.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">2.2 Influence of ionic liquid and tertiary alcohols on [18F]fluorination.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug development is very expensive and a fight against time. PET offers possibilities to speed up this process by adding unique in vivo information on pharmacokinetics/dynamics of a drug at an early stage. This information can help decision makers to move the drug in the drug development process or to decide to stop further developments. This unique and complete book highlights the different ways PET can be used and describes the latest trends in the various disciplines within nuclear medicine to further improve methodologies and increase the number of tools to accelerate drug development. Var.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh97007921</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Tomography, Emission.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85135956</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmaceutical technology.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85100590</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Design.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh88001157</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Technology, Pharmaceutical</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Positron-Emission Tomography</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Tomography, Emission-Computed</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D014055</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Développement.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Tomographie par émission.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Techniques pharmaceutiques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Conception.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Drug Guides.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Nursing</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacy.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs</subfield><subfield code="x">Design</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmaceutical technology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tomography, Emission</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Van Waarde, Aren.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paans, Anne M. J.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Elsinga, Philip H.</subfield><subfield code="t">Trends on the Role of PET in Drug Development.</subfield><subfield code="d">Singapore : World Scientific, ©2012</subfield><subfield code="z">9789814317733</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457199</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH25565236</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">123Library</subfield><subfield code="b">123L</subfield><subfield code="n">114803</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL919100</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10563508</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">457199</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">7223101</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn794328395 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:18:24Z |
| institution | BVB |
| isbn | 9789814317740 9814317748 |
| language | English |
| oclc_num | 794328395 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (799 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | World Scientific, |
| record_format | marc |
| spelling | Elsinga, Philip H. Trends on the Role of PET in Drug Development. Singapore : World Scientific, 2012. 1 online resource (799 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier The Editors; Contributors; Preface; 1 Introduction on PET. Description of Basics and Principles Aren van Waarde; References; 2 Drug Development in the Pharmaceutical Industry Adrian D. Nunn; 1. Introduction; 2. Drug Approval Rates; 3. Costs of Each Stage; 4. Efficiency of Drug Development; 5. Changing Healthcare Model; 6. Comparative Effectiveness; 7. Personalized Medicine; 8. Regulatory Issues; 9. Conclusions; References; 3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines R. Paul Maguire; 1. Summary. 2. FDA Critical Path Initiative -- Drug Development Challenge3. Drug Development Process Decision Points; 3.1 Phases of drug development; 4. Imaging Biomarkers in General; 4.1 Imaging biomarkers for early decision making; 4.2 Diagnostics; 4.2.1 Smaller likelihood ratio; 4.3 Markers of disease; 5. Imaging Biomarkers Other than Molecular Imaging; 6. Biomarkers Other than Imaging; 7. Receptor Occupancy; 7.1 Determination of in vivo KD; 7.2 Typical RO study designs; 7.3 Assumptions; 8. Thresholds for Decision Making; 8.1 Efficacy and occupancy at G-coupled protein receptors. 9. Sources of Imprecision9.1 Instrument sensitivity; 9.2 Variability of PK; 10. Safety of Molecular Imaging Probes; 11. Ideal Molecular Imaging Ligand; 11.1 Safety; 11.2 Affinity; 11.3 Non-specific binding; 11.4 Selectivity; 11.5 Easy deployment and implementation; 12. Models of PET-Pharmacokinetics -- Data Analysis; 13. Industry Academic Collaboration; 13.1 Labeling available chemical matter; 13.2 Translational imaging; 13.3 Customized therapies -- companion diagnostics; 14. Summary; References; 4 What is the Role of Positron Emission Tomography in Drug Development? Timothy J. McCarthy. 1. Introduction2. Biomarker Definitions; 3. PET as a Tool for Proof of Target; 4. PET as a Tool for Proof of Mechanism; 5. PET as a Tool for Proof of Efficacy; 6. Summary and Conclusions; References; 5 Review of 11C Preparations and Examples in Drug Development Farhad Karimi and Bengt Långstrom; 1. Choice of Radionuclide; 2. 11C Compounds; 2.1 11C precursor; 2.2 11C chemistry based on [11C]methyl iodide/triflate; 2.2.1 Palladium-mediated C-C bond formation; 2.3 11C Chemistry based on [11C]carbon monoxide; 2.3.1 [11C]Carbon monoxide insertion. 2.3.2 Organo metals mediated 11C-carbonylation reaction2.3.2.1 Palladium-mediated 11C-carbonylation reaction; 2.3.2.2 Selenium-mediated 11C-carbonylation reaction; 2.3.2.3 Rhodium-mediated 11C-carbonylation reaction; 2.3.2.4 Radical-mediated carbonylation reactions; 3. Endogenous PET-Radiopharmaceuticals; 4. Automated Synthetic Devices; References; 6 The Role of Recent Development of 18F Radiochemistry in Drug Development Farhad Karimi and Bengt Långstrom; 1. Introduction; 2. Nucleophilic 18F Fluorination; 2.1 Basic chemistry. 2.2 Influence of ionic liquid and tertiary alcohols on [18F]fluorination. Drug development is very expensive and a fight against time. PET offers possibilities to speed up this process by adding unique in vivo information on pharmacokinetics/dynamics of a drug at an early stage. This information can help decision makers to move the drug in the drug development process or to decide to stop further developments. This unique and complete book highlights the different ways PET can be used and describes the latest trends in the various disciplines within nuclear medicine to further improve methodologies and increase the number of tools to accelerate drug development. Var. Print version record. Includes bibliographical references and index. Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Tomography, Emission. http://id.loc.gov/authorities/subjects/sh85135956 Pharmaceutical technology. http://id.loc.gov/authorities/subjects/sh85100590 Drugs Design. http://id.loc.gov/authorities/subjects/sh88001157 Drug Design Technology, Pharmaceutical Positron-Emission Tomography Tomography, Emission-Computed https://id.nlm.nih.gov/mesh/D014055 Médicaments Développement. Tomographie par émission. Techniques pharmaceutiques. Médicaments Conception. MEDICAL Drug Guides. bisacsh MEDICAL Nursing Pharmacology. bisacsh MEDICAL Pharmacology. bisacsh MEDICAL Pharmacy. bisacsh Drugs Design fast Drug development fast Pharmaceutical technology fast Tomography, Emission fast Van Waarde, Aren. Paans, Anne M. J. Print version: Elsinga, Philip H. Trends on the Role of PET in Drug Development. Singapore : World Scientific, ©2012 9789814317733 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457199 Volltext |
| spellingShingle | Elsinga, Philip H. Trends on the Role of PET in Drug Development. The Editors; Contributors; Preface; 1 Introduction on PET. Description of Basics and Principles Aren van Waarde; References; 2 Drug Development in the Pharmaceutical Industry Adrian D. Nunn; 1. Introduction; 2. Drug Approval Rates; 3. Costs of Each Stage; 4. Efficiency of Drug Development; 5. Changing Healthcare Model; 6. Comparative Effectiveness; 7. Personalized Medicine; 8. Regulatory Issues; 9. Conclusions; References; 3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines R. Paul Maguire; 1. Summary. 2. FDA Critical Path Initiative -- Drug Development Challenge3. Drug Development Process Decision Points; 3.1 Phases of drug development; 4. Imaging Biomarkers in General; 4.1 Imaging biomarkers for early decision making; 4.2 Diagnostics; 4.2.1 Smaller likelihood ratio; 4.3 Markers of disease; 5. Imaging Biomarkers Other than Molecular Imaging; 6. Biomarkers Other than Imaging; 7. Receptor Occupancy; 7.1 Determination of in vivo KD; 7.2 Typical RO study designs; 7.3 Assumptions; 8. Thresholds for Decision Making; 8.1 Efficacy and occupancy at G-coupled protein receptors. 9. Sources of Imprecision9.1 Instrument sensitivity; 9.2 Variability of PK; 10. Safety of Molecular Imaging Probes; 11. Ideal Molecular Imaging Ligand; 11.1 Safety; 11.2 Affinity; 11.3 Non-specific binding; 11.4 Selectivity; 11.5 Easy deployment and implementation; 12. Models of PET-Pharmacokinetics -- Data Analysis; 13. Industry Academic Collaboration; 13.1 Labeling available chemical matter; 13.2 Translational imaging; 13.3 Customized therapies -- companion diagnostics; 14. Summary; References; 4 What is the Role of Positron Emission Tomography in Drug Development? Timothy J. McCarthy. 1. Introduction2. Biomarker Definitions; 3. PET as a Tool for Proof of Target; 4. PET as a Tool for Proof of Mechanism; 5. PET as a Tool for Proof of Efficacy; 6. Summary and Conclusions; References; 5 Review of 11C Preparations and Examples in Drug Development Farhad Karimi and Bengt Långstrom; 1. Choice of Radionuclide; 2. 11C Compounds; 2.1 11C precursor; 2.2 11C chemistry based on [11C]methyl iodide/triflate; 2.2.1 Palladium-mediated C-C bond formation; 2.3 11C Chemistry based on [11C]carbon monoxide; 2.3.1 [11C]Carbon monoxide insertion. 2.3.2 Organo metals mediated 11C-carbonylation reaction2.3.2.1 Palladium-mediated 11C-carbonylation reaction; 2.3.2.2 Selenium-mediated 11C-carbonylation reaction; 2.3.2.3 Rhodium-mediated 11C-carbonylation reaction; 2.3.2.4 Radical-mediated carbonylation reactions; 3. Endogenous PET-Radiopharmaceuticals; 4. Automated Synthetic Devices; References; 6 The Role of Recent Development of 18F Radiochemistry in Drug Development Farhad Karimi and Bengt Långstrom; 1. Introduction; 2. Nucleophilic 18F Fluorination; 2.1 Basic chemistry. Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Tomography, Emission. http://id.loc.gov/authorities/subjects/sh85135956 Pharmaceutical technology. http://id.loc.gov/authorities/subjects/sh85100590 Drugs Design. http://id.loc.gov/authorities/subjects/sh88001157 Drug Design Technology, Pharmaceutical Positron-Emission Tomography Tomography, Emission-Computed https://id.nlm.nih.gov/mesh/D014055 Médicaments Développement. Tomographie par émission. Techniques pharmaceutiques. Médicaments Conception. MEDICAL Drug Guides. bisacsh MEDICAL Nursing Pharmacology. bisacsh MEDICAL Pharmacology. bisacsh MEDICAL Pharmacy. bisacsh Drugs Design fast Drug development fast Pharmaceutical technology fast Tomography, Emission fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh97007921 http://id.loc.gov/authorities/subjects/sh85135956 http://id.loc.gov/authorities/subjects/sh85100590 http://id.loc.gov/authorities/subjects/sh88001157 https://id.nlm.nih.gov/mesh/D014055 |
| title | Trends on the Role of PET in Drug Development. |
| title_auth | Trends on the Role of PET in Drug Development. |
| title_exact_search | Trends on the Role of PET in Drug Development. |
| title_full | Trends on the Role of PET in Drug Development. |
| title_fullStr | Trends on the Role of PET in Drug Development. |
| title_full_unstemmed | Trends on the Role of PET in Drug Development. |
| title_short | Trends on the Role of PET in Drug Development. |
| title_sort | trends on the role of pet in drug development |
| topic | Drug development. http://id.loc.gov/authorities/subjects/sh97007921 Tomography, Emission. http://id.loc.gov/authorities/subjects/sh85135956 Pharmaceutical technology. http://id.loc.gov/authorities/subjects/sh85100590 Drugs Design. http://id.loc.gov/authorities/subjects/sh88001157 Drug Design Technology, Pharmaceutical Positron-Emission Tomography Tomography, Emission-Computed https://id.nlm.nih.gov/mesh/D014055 Médicaments Développement. Tomographie par émission. Techniques pharmaceutiques. Médicaments Conception. MEDICAL Drug Guides. bisacsh MEDICAL Nursing Pharmacology. bisacsh MEDICAL Pharmacology. bisacsh MEDICAL Pharmacy. bisacsh Drugs Design fast Drug development fast Pharmaceutical technology fast Tomography, Emission fast |
| topic_facet | Drug development. Tomography, Emission. Pharmaceutical technology. Drugs Design. Drug Design Technology, Pharmaceutical Positron-Emission Tomography Tomography, Emission-Computed Médicaments Développement. Tomographie par émission. Techniques pharmaceutiques. Médicaments Conception. MEDICAL Drug Guides. MEDICAL Nursing Pharmacology. MEDICAL Pharmacology. MEDICAL Pharmacy. Drugs Design Drug development Pharmaceutical technology Tomography, Emission |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457199 |
| work_keys_str_mv | AT elsingaphiliph trendsontheroleofpetindrugdevelopment AT vanwaardearen trendsontheroleofpetindrugdevelopment AT paansannemj trendsontheroleofpetindrugdevelopment |